Dr Bing Wang
Research Associate
Adelaide Medical School
Faculty of Health and Medical Sciences
My research has primarily focused on projects evaluating the impact, effectiveness, and cost-effectiveness of various vaccine programs. My journey began with a medical degree in China, following which I gained valuable industry experience, holding positions in both pharmaceutical and clinical research organizations. This practical exposure equipped me with in-depth knowledge of population health and clinical research. After completing a Master's degree in Public Health, I continued the research journey as a PhD student, specialising in the fields of vaccine-preventable diseases, vaccinology, and health economics. My Field-Weighted Citation Impact (FWCI) stands at 2.90 over the past five years (2020-2024), highlighting that my research performance exceeds the global average by 190%. My research has a broader impact beyond academia, positively contributing to the health and well-being of individuals and communities.
My research has played a vital role in supporting government policy-making at the state, national, and global levels. The outcomes of my research have been instrumental in various instances, cited in the government work report (SA meningococcal serogroup B vaccine program public report), as well as utilised in published and unpublished cost-effectiveness evaluations in Australia and other countries. The results were provided to influential bodies such as the Australian Technical Advisory Group on Immunisation (ATAGI) and the Pharmaceutical Benefits Advisory Committee (PBAC) to inform government funding decisions.
I have led meningococcal serogroup B vaccine (4CMenB) program evaluation projects. In October 2018, South Australia launched a world first meningococcal B vaccine program, which is the first long-term program to provide free 4CMenB vaccine to infants, children, adolescents, and young people. The collaboration on evaluation of the state 4CMenB vaccination programs offered a unique opportunity to assess the vaccine effectiveness and impact of 4CMenB vaccine against invasive meningococcal B disease and gonorrhoea in these high-risk age groups. Two papers published in the Lancet Infectious Diseases and the Journal of Infection present the results of the evaluation of the world's first meningococcal serogroup B vaccine program in South Australia for infants and adolescents. Based on results of this evaluation, showing high vaccine effectiveness against meningococcal B disease in infants and adolescents, the Health Minister made the decision to continue the program indefinitely in South Australia in July 2021. The Czech Republic and New Zealand have subsequently introduced a meningococcal serogroup B vaccine program for adolescents and infants based on these published results. As this is the first ongoing program for adolescents, we were able to demonstrate moderate vaccine effectiveness against gonorrhoea in adolescents who received meningococcal serogroup B vaccine, through cross-protection. The Joint Committee on Vaccination and Immunisation (JCVI) in the UK, equivalent to the Australian Technical Advisory Group on Immunisation (ATAGI) in Australia, has recommended the initiation of a targeted program for 4CMenB to prevent gonorrhoea in individuals at the highest risk of infection, drawing from the findings of our and other evaluation results.
The collaboration with Communicable Disease Control Branch at SA Health and Prevention & Population Health at Wellbeing SA has played a crucial role in enhancing our understanding of the diseases impact on communities and informing evidence-based strategies for public health response. The access to valuable data, specialised expertise, and diverse perspectives offered by the Communicable Disease Control Branch at SA Health and Prevention & Population Health at Wellbeing SA has expanded the scope of my research activities, enabling me to undertake more comprehensive and impactful studies. Our collaborative efforts have been marked by a shared commitment to excellence, scientific rigor, and the pursuit of positive health outcomes for the South Australian community. Through the exchange of knowledge, resources, and expertise, we have been able to address pressing research questions and produce high-quality publications. Six papers have emerged from our collaboration reflect the depth and breadth of our joint accomplishments. I have established strong collaborative relationships with external researchers in Australia and the UK. The collective efforts have yielded substantial research outcomes.
I am currently a member of the European Society for Paediatric Infectious Diseases (ESPID), the European Meningococcal and Haemophilus Disease Society (EMGM), and the Healthy Development Adelaide (HDA). In July 2024, I was invited to join the Conference Advisory Committee for the National Communicable Disease and Immunisation Conference (15 members). I was invited to be the NHMRC e-Asia Joint Research Program reviewer on 12 April 2021 and 26 Mar 2024. I was a member of the Early and Mid-Career Research Council at the Robinson Research Institute (RRI), The University of Adelaide, from 2019 to 2020. I provided input on key decisions and advice to the RRI Executive Committee in support of achieving the aims of the Institute. In 2022, I was appointed as Lead, Health Economics, for the Vaccines and Infectious Diseases Group, led by Prof Marshall. I have overseen the health economic component of research projects such as study design and collaboration with external health economic researchers. I was also a member of the interview panel for MBBS student selections at the University of Adelaide.
My research interests are immunisation, health behaviours, vaccine effectiveness, cost-effectiveness and adolescent health.
-
Appointments
Date Position Institution name 2022 - ongoing Postdoctoral Research Fellow University of Adelaide 2021 - 2022 Research Associate University of Adelaide 2019 - 2022 Medical Scientist Women's and Children's Hospital 2019 - 2019 Research Associate University of Adelaide -
Language Competencies
Language Competency Chinese (Mandarin) Can read, write, speak, understand spoken and peer review English Can read, write, speak, understand spoken and peer review -
Education
Date Institution name Country Title 2014 - 2019 University of Adelaide Australia PhD (Medicine) 2012 - 2014 University of Adelaide Australia Master of Philosophy (Public Health) 1994 - 1999 Capital Medical University China Bachelor of Medicine -
Research Interests
-
Journals
Year Citation 2024 Lyu, Y., Choong, A., Chow, E. P. F., Seib, K. L., Marshall, H. S., Unemo, M., . . . Ong, J. J. (2024). Vaccine value profile for Neisseria gonorrhoeae.. Vaccine, 42(19), S42-S69.
Scopus5 Europe PMC12024 Wang, B., Andraweera, P., Danchin, M., Blyth, C. C., Vlaev, I., Ong, J., . . . Marshall, H. (2024). Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics. BMJ Open, 14(2), 076194-1-076194-9.
2024 Mohammed, H., Peut, C., McMillan, M., Wang, B., Sullivan, T. R., & Marshall, H. S. (2024). The Role of Schools in Meningococcal Carriage among Adolescents and Young Adults in South Australia. Pediatric Infectious Disease Journal, 43(7), e249-e251.
2024 Marshall, H., Ward, J., Wang, B., Andraweera, P., McMillan, M., Flood, L., . . . Lahra, M. M. (2024). Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol. BMJ Open, 14(5), 8 pages.
Scopus12024 Wang, B., Mohammed, H., Andraweera, P., McMillan, M., & Marshall, H. (2024). Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis. Journal of Infection, 89(3), 10 pages.
2024 Wang, B., Seib, K. L., & Marshall, H. (2024). The future role of vaccination in prevention of Neisseria gonorrhoeae. Microbiology Australia, 45(3), 117-121.
Scopus12023 Mohammed, H., Pham-Tran, D. D., Yeoh, Z. Y. M., Wang, B., McMillan, M., Andraweera, P. H., & Marshall, H. S. (2023). A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). Vaccines, 11(2), 1-19.
Scopus24 WoS3 Europe PMC212023 Wang, B., Andraweera, P., Elliott, S., Mohammed, H., Lassi, Z., Twigger, A., . . . Marshall, H. (2023). Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis. The Pediatric Infectious Disease Journal, 42(3), 232-239.
Scopus26 WoS11 Europe PMC202023 Wang, B., Giles, L., Andraweera, P., McMillan, M., Almond, S., Beazley, R., . . . Marshall, H. (2023). 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post program implementation. Journal of Infection, 87(2), 95-102.
Scopus18 Europe PMC72023 Andraweera, P. H., Wang, B., Danchin, M., Blyth, C., Vlaev, I., Ong, J., . . . Marshall, H. S. (2023). Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccines among pregnant women (the EPIC study): study protocol. Trials, 24(1), 454-1-454-8.
Scopus1 Europe PMC12023 Wang, B., & Marshall, H. S. (2023). A new era for equity in meningococcal disease prevention. The Lancet Infectious Diseases, 23(12), 1329-1330.
Scopus12023 Wang, B., McDonough, J., Chen, G., Ong, J. J., & Marshall, H. (2023). Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination. Vaccine, 41(51), 7608-7617.
Scopus12022 Wang, B., Giles, L., Andraweera, P., McMillan, M., Almond, S., Beazley, R., . . . Marshall, H. (2022). Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. The Lancet Infectious Diseases, 22(7), 1011-1020.
Scopus53 WoS20 Europe PMC272022 Wang, B., Nolan, R., Krumeich, B., D'Onise, K., & Marshall, H. (2022). COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia. Human Vaccines and Immunotherapeutics, 18(5), 1-9.
Scopus7 WoS2 Europe PMC52021 Marshall, H. S., Andraweera, P. H., Wang, B., McMillan, M., Koehler, A. P., Lally, N., . . . Flood, L. (2021). Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Human Vaccines and Immunotherapeutics, 17(5), 1450-1454.
Scopus10 WoS7 Europe PMC42021 McMillan, M., Wang, B., Koehler, A. P., Sullivan, T. R., & Marshall, H. S. (2021). Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents.. Clin Infect Dis, 73(1), e233-e237.
Scopus26 WoS10 Europe PMC122021 Wang, B., Nolan, R., & Marshall, H. (2021). Covid-19 immunisation, willingness to be vaccinated and vaccination strategies to improve vaccine uptake in Australia. Vaccines, 9(12), 1467.
Scopus17 WoS7 Europe PMC122020 Marshall, H. S., Koehler, A. P., Wang, B., A'Houre, M., Gold, M., Quinn, H., . . . Macartney, K. (2020). Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine, 38(37), 5914-5922.
Scopus15 WoS7 Europe PMC62019 Wang, B., Santoreneos, R., Giles, L., Haji Ali Afzali, H., & Marshall, H. (2019). Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine, 37(21), 2768-2782.
Scopus140 WoS102 Europe PMC752019 Wang, B., Hajiali Afzali, H., Giles, L., & Marshall, H. (2019). Lifetime costs of invasive meningococcal disease: a Markov model approach. Vaccine, 37(46), 6885-6893.
Scopus6 WoS2 Europe PMC62019 Marshall, H., McMillan, M., Wang, B., Booy, R., Afzali, H., Buttery, J., . . . Barton, B. (2019). AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.. BMJ Open, 9(12), e032583.
Scopus4 WoS3 Europe PMC32018 Wang, B., Santoreneos, R., Afzali, H., Giles, L., & Marshall, H. (2018). Costs of invasive meningococcal disease: a global systematic review. PharmacoEconomics, 36(10), 1201-1222.
Scopus23 WoS16 Europe PMC172017 Wang, B., Chen, G., Ratcliffe, J., Afzali, H., Giles, L., & Marshall, H. (2017). Adolescent values for immunisation programs in Australia: a discrete choice experiment. PLoS ONE, 12(7), e0181073-1-e0181073-14.
Scopus20 WoS16 Europe PMC162016 Marshall, H., Wang, B., Wesselingh, S., Snape, M., & Pollard, A. J. (2016). Control of invasive meningococcal disease: Is it achievable?. International Journal of Evidence-Based Healthcare, 14(1), 3-12.
Scopus9 WoS9 Europe PMC32016 Wang, B., Giles, L., Afzali, H., Clarke, M., Ratcliffe, J., Chen, G., & Marshall, H. (2016). Adolescent confidence in immunisation: assessing and comparing attitudes of adolescents and adults. Vaccine, 34(46), 5595-5603.
Scopus13 WoS12 Europe PMC92014 Wang, B., Clarke, M., Hajiali Afzali, H., & Marshall, H. (2014). Community, parental and adolescent awareness and knowledge of meningococcal disease. Vaccine, 32(18), 2042-2049.
Scopus22 WoS18 Europe PMC192014 Wang, B., Clarke, M., Thomas, N., Howell, S., Afzali, H., & Marshall, H. (2014). The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatric Infectious Disease Journal, 33(3), 316-318.
Scopus22 WoS24 Europe PMC122014 Wang, B., Haji Ali Afzali, H., & Marshall, H. (2014). The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine, 32(37), 4791-4798.
Scopus32 WoS23 Europe PMC19 -
Report for External Bodies
Year Citation 2022 McMillan, M., Mohammed, H., Wang, B., Saunders, L., Clarke, M., McDonough, J., & Marshall, H. (2022). Review of the COVID-19 vaccine program in South Australia. 2021 Elliott, S., Andraweera, P., McMillan, M., Evans, S., Wang, B., Mohammed, H., . . . Marshall, H. (2021). Review of 2020 Influenza vaccine distribution in South Australia.
Chief Investigator: NHMRC Centre for Research Excellence in Neisseria Disease Control (APP2035525)
Associate Investigator: NHMRC Partnership project (APP2014684): Novel strategies to improve protection for pregnant women and medically at risk children from influenza and COVID-19
Barbara Kidman Women’s Fellowship, The University of Adelaide, 2024 ($27,000)
Faculty of Health and Medical Sciences Early Grant Development Award, The University of Adelaide, 2023 ($36,500)
Faculty of Health and Medical Sciences Emerging Leaders Development Award, The University of Adelaide, 2021 ($40,000)
Australian Federation of University Women SA Inc. (AFUW) Trust Postdoctoral Grant, The University of Adelaide, 2023 ($5,000)
Healthy Development Adelaide (HDA) Travel and Development Grant, 2024 ($500)
Women’s and Children’s Hospital Foundation 2022 Early Career Research Publication Award, 2023 ($1000)
Robinson Research Institute Travel Grant, The University of Adelaide, 2023 ($1,000)
Faculty of Health and Medical Sciences Research Travel Award, The University of Adelaide, 2023 ($1,000)
Faculty of Health and Medical Sciences Executive Dean’s Award for Research Excellence (Early Career Researcher), The University of Adelaide, 2023 ($275)
Healthy Development Adelaide (HDA) Early Career Researcher (ECR) Publication Award, 2022 ($500)
Robinson Research Institute Travel Grant, The University of Adelaide, 2019 ($1,000)
Faculty of Health and Medical Sciences Research Travel Award, The University of Adelaide, 2019 ($1,000)
Adelaide Medical School Research Travel Award, The University of Adelaide, 2017 ($1000)
European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting Travel Award, 2017 (Approx $5000)
School of Medicine Research Travel Award, The University of Adelaide, 2016 ($1000)
Alice Davey Award 2016, The University of Adelaide (team award; $500)
Early in Career Public Health Award in Immunisation, National Immunisation Conference, 2014 ($500)
Channel 7 Children's Research Foundation PhD Top-up Scholarship, 2014-2018 ($5,000 per year)
Australian Postgraduate Award (APA) Scholarship, The University of Adelaide, 2014 – 2018 (Approx. $25,000 per year)
Divisional Scholarship, The University of Adelaide, 2012-2013 (Approx. $12,000 per year)
First Class Scholarship, Capital Medical University, 1999 (Approx. $200)
Excellent Student Award, Capital Medical University, 1999 (Approx. $100)
-
Committee Memberships
Date Role Committee Institution Country 2024 - ongoing Member Conference Advisory Committee for the national Communicable Diseases & Immunisation Conference Public Health Association of Australia Australia 2019 - 2020 Member Early and Mid-Career Research Council Robinson Research Institute (RRI), University of Adelaide Australia -
Review, Assessment, Editorial and Advice
Date Title Type Institution Country 2024 - 2024 NHMRC e-Asia Joint Program review panel Grant Assessment NHMRC - 2020 - ongoing Poster assessor for the Florey Postgraduate Research Conference & Robinson Research Institute Symposium Peer Review University of Adelaide - 2019 - ongoing Abstract reviewer Peer Review Public Health Association of Australia -
Connect With Me
External Profiles